Assessing Next Generation Self-Replicating RNA Vectors to Enable New Approaches to Immunotherapy

Time: 11:00 am
day: Focus Day


  • Understanding how next generation synthetic srRNA vectors can lower dose by orders of magnitude compared to current srRNA designs
  • Developing new srRNA products requires independent optimisation of vectors, gene inserts, and delivery
  • Improving srRNA bioactivity to enable new approaches for immunotherapies in oncology
  • Following these platform improvements, Replicate Biosciences have designed a srRNA vaccine targeting resistance mutations in endocrine receptor positive breast cancer